Full Text View
Tabular View
No Study Results Posted
Related Studies
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
This study has been completed.
Study NCT00004189   Information provided by National Cancer Institute (NCI)
First Received: January 21, 2000   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Small Intestine Cancer
Additional conditions recognized in this trial
Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
filgrastim
becatecarin
cisplatin
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Texas
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services